MAPT and Alzheimer disease: Also, an intrinsic limitation of the SomaScan platform is that phosphorylated tau isoforms such as p-tau181 and p-tau217, which are well-established plasma biomarkers for AD diagnosis and progression, are not captured by the current SomaScan panel.